Merck & Co Inc (NYSE:MRK) announced topline results from two Phase 3 trials evaluating V116, the company’s investigational 21-valent pneumococcal conjugate vaccine in vaccine-naïve and previously vaccinated individuals.
If approved, V116 would be the first pneumococcal conjugate vaccine specifically designed for adults.
Results from the STRIDE-3 trial demonstrated statistically significant immune responses compared to PCV20 (pneumococcal 20-valent conjugate vaccine) in vaccine-naïve adults for serotypes common to both vaccines as assessed by serotype-specific opsonophagocytic activity (OPA) 30 days post-vaccination.
Positive immune responses were also observed for serotypes unique to V116.
Additionally, results from STRIDE-6 demonstrated that V116 was immunogenic for all 21 pneumococcal serotypes in the vaccine among adults who received a pneumococcal vaccine at least one year before the study.
In both studies, V116 had a safety profile comparable to the comparator.
Price Action: MRK shares are down 0.88% at $106.20 on the last check Thursday.
